However hard the market slams a stock, there's always the chance it'll come bouncing right back. We'll consult our Motley Fool CAPS community to find shares on the rebound, examining one specific sector of the economy in search of companies with rising CAPS ratings.
There are 295 stocks listed under "drugs" in the CAPS screener, more than a handful of which carry well-respected four- and five-star ratings. Those accolades signal our 170,000 CAPS members' confidence that these stocks will beat the market in the months ahead. Let's see what members are saying about the ones below:
CAPS Rating Today
52-Wk Price Change
5-Yr. Growth Rate
Source: Motley Fool CAPS; Yahoo! Finance. NA = not available.
Take one and call me in the morning
The markets may be feeling better about the economy, now that a few reports have offset much of the drumbeat of negativism we've seen. The S&P 500 has risen 8% over last year, but surprisingly, CAPS drug stocks have done even better; the average stock in this category up 16% from the year-ago period.
Those average returns got a boost from performers such as Avanir Pharmaceuticals
Don't consider Zalicus a zero just yet, though. It's generating royalties from its pain medication Exalgo, which it licenses in the U.S. to Covidien. The company's R&D agreements with a number of organizations and companies, including Amgen and Novartis, also contribute significant revenue.
More than 95% of the CAPS members who've rated Zalicus believe that its focus on new classes of analgesics for the treatment of both acute and chronic pain will enable it to outperform the markets going forward. You can head over to the Zalicus CAPS page and let us know whether you think this biotech will relieve investors' aches.
Some spring in its step
As good as AEterna Zentaris' returns were, its fortunes have been tied to those of Keryx Pharmaceuticals
In addition to this short-term catalyst, highly rated CAPS All-Star member tenmiles notes AEterna's promising pipeline:
Debt free oncology drug development company-multiple opportunities in the pipeline-could be a runner down the road with Perifosine approval-like the risk/reward after retracement back to the $1.27 level
Only you can determine whether AEterna Zentaris is right for your portfolio. Add it to your stock watchlist and get all our Foolish news and analysis about it aggregated for you.
Driving a bargain
Is this a case of two strikes, you're out? Amylin Pharmaceuticals, Alkermes, and to a lesser extent Eli Lilly
Amylin's stock might have been oversold after the announcement, as pchop123 suggests, and analysts have even weighed in that it now offers an attractive valuation, because Bydureon could still become a blockbuster drug. Some even think it can come back within six months.
Let us know on the Amylin Pharmaceuticals CAPS page (or in the comments section below) whether the third time will be the charm.
The ball's in your court
Many factors go into whether a stock is a buy or sell, so it pays to start your own research on these stocks on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made, all from a stock's CAPS page. Head over to CAPS today and share your thoughts with other investor analysts on whether you think these stocks are ready to bound higher.
Novartis is a Motley Fool Global Gains selection. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
More from The Motley Fool
Keryx Biopharma Down 17% Despite Drug Approval
Shares took a nosedive after the company's earnings report, but with a new FDA approval under its belt, this could be a buying opportunity for investors.
Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise
The company's winning new customers, but that didn't help its third-quarter financials.
Keryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't Matter
It was another down month for the small-cap biopharma, but this pending regulatory news promises to turn the company's fortunes around.